The novel role of LDHA/LDHB in the prognostic value and tumor-immune infiltration in clear cell renal cell carcinoma (#83877)

First submission

Guidance from your Editor

Please submit by **1 May 2023** for the benefit of the authors (and your token reward) .

Structure and Criteria
Please read the 'Structure and Criteria' page for general guidance.

Custom checks
Make sure you include the custom checks shown below, in your review.

Author notes
Have you read the author notes on the guidance page?

Raw data check
Review the raw data.

Image check
Check that figures and images have not been inappropriately manipulated.

If this article is published your review will be made public. You can choose whether to sign your review. If uploading a PDF please remove any identifiable information (if you want to remain anonymous).

Files

Download and review all files from the materials page.

12 Figure file(s)
2 Table file(s)
2 Raw data file(s)

Custom checks

Human participant/human tissue checks

- Have you checked the authors ethical approval statement?
- Does the study meet our article requirements?
- Has identifiable info been removed from all files?
- Were the experiments necessary and ethical?

Cell line checks

- Is the correct provenance of the cell line described?

Structure and Criteria

Structure your review

The review form is divided into 5 sections. Please consider these when composing your review:

1. **BASIC REPORTING**
2. **EXPERIMENTAL DESIGN**
3. **VALIDITY OF THE FINDINGS**
4. General comments
5. Confidential notes to the editor

You can also annotate this PDF and upload it as part of your review

When ready submit online.

Editorial Criteria

Use these criteria points to structure your review. The full detailed editorial criteria is on your guidance page.

BASIC REPORTING

- Clear, unambiguous, professional English language used throughout.
- Intro & background to show context. Literature well referenced & relevant.
- Structure conforms to PeerJ standards, discipline norm, or improved for clarity.
- Figures are relevant, high quality, well labelled & described.
- Raw data supplied (see PeerJ policy).

EXPERIMENTAL DESIGN

- Original primary research within Scope of the journal.
- Research question well defined, relevant & meaningful. It is stated how the research fills an identified knowledge gap.
- Rigorous investigation performed to a high technical & ethical standard.
- Methods described with sufficient detail & information to replicate.

VALIDITY OF THE FINDINGS

- Impact and novelty not assessed. *Meaningful* replication encouraged where rationale & benefit to literature is clearly stated.
- All underlying data have been provided; they are robust, statistically sound, & controlled.
- Conclusions are well stated, linked to original research question & limited to supporting results.

Standout reviewing tips

The best reviewers use these techniques

Tip	*Example*
Support criticisms with evidence from the text or from other sources	*Smith et al (J of Methodology, 2005, V3, pp 123) have shown that the analysis you use in Lines 241-250 is not the most appropriate for this situation. Please explain why you used this method.*
Give specific suggestions on how to improve the manuscript	*Your introduction needs more detail. I suggest that you improve the description at lines 57- 86 to provide more justification for your study (specifically, you should expand upon the knowledge gap being filled).*
Comment on language and grammar issues	*The English language should be improved to ensure that an international audience can clearly understand your text. Some examples where the language could be improved include lines 23, 77, 121, 128 – the current phrasing makes comprehension difficult. I suggest you have a colleague who is proficient in English and familiar with the subject matter review your manuscript, or contact a professional editing service.*
Organize by importance of the issues, and number your points	*1. Your most important issue* *2. The next most important item* *3. …* *4. The least important points*
Please provide constructive criticism, and avoid personal opinions	*I thank you for providing the raw data, however your supplemental files need more descriptive metadata identifiers to be useful to future readers. Although your results are compelling, the data analysis should be improved in the following ways: AA, BB, CC*
Comment on strengths (as well as weaknesses) of the manuscript	*I commend the authors for their extensive data set, compiled over many years of detailed fieldwork. In addition, the manuscript is clearly written in professional, unambiguous language. If there is a weakness, it is in the statistical analysis (as I have noted above) which should be improved upon before Acceptance.*

The novel role of LDHA/LDHB in the prognostic value and tumor-immune infiltration in clear cell renal cell carcinoma

Jie Chen [1], **Fei Wu** [2, 3], **Yuanxin Xing** [4], **Qingyong Liu** [Corresp., 3], **Zuohui Zhao** [Corresp. 5]

[1] Department of Urology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China

[2] Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong First Medical University &Shandong Academy of Medical Sciences, Jinan, Shandong, China

[3] Department of Urology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China

[4] Central Laboratory, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China

[5] Pediatric Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China

Corresponding Authors: Qingyong Liu, Zuohui Zhao
Email address: lqylbc@163.com, zhaozuohui@126.com

Lactate dehydrogenase (LDH), a crucial glycolytic enzyme, mediates the metabolic plasticity of cancer cells, whereas its clinical significance in renal cell carcinoma (RCC) is poorly understood. Herein, we examined the prognostic significance of the two primary components of LDH, i.e., LDHA and LDHB, in clear cell RCC (ccRCC) patients and further explored their association with immune infiltration in ccRCC. In this study, the expression levels of LDHA and LDHBwere examined in ccRCC and adjacent normal tissues by Gene Expression Profiling Interactive Analysis 2 (GEPIA2), UALCAN, and western blotting (WB) analyses, and their prognostic values were estimated in 150 ccRCC and 30 adjacent normal tissues by immunohistochemistry (IHC) analysis. The relationship to immune infiltration of *LDHA* and *LDHB* genes was further investigated using tumor immune estimation resource 2 (TIMER2) and Tumor-Immune System Interactions and DrugBank (TISIDB) databases, respectively. Public databases and WB analyses demonstrated higher LDHA and lower LDHB in ccRCC than in non-tumor tissues. IHC analysis revealed that LDHA and LDHB expression profiles were significantly associated with tumor grade, stage, size, and overall survival (OS). Univariate survival analysis displayed that high grade, advanced stage, large tumor, metastasis, high LDHA, and low LDHB expression were significantly associated with a poorer OS, and multivariate analysis revealed tumor stage and LDHB were identified as independent predictors for OS in patients with ccRCC. Further TIMER and TISIDB analyses demonstrated that *LDHA* and *LDHB* expression was significantly related to multiple immune cells and immune inhibitors in over 500 ccRCC patients. These findings revealed that LDHB was an independent favorable predictor, and LDHA and LDHB correlated with tumor immune infiltrates in ccRCC patients, which indicated LDHA/LDHB

could be implicated in the tumorigenesis of ccRCC and might be potential therapeutic targets for patients with ccRCC.

The novel role of LDHA/LDHB in the prognostic value and tumor-immune infiltration in clear cell renal cell carcinoma

Jie Chen[1], Fei Wu[2,3], Yuanxin Xing[4], Qingyong Liu[3*], Zuohui Zhao[5*]

[1] Department of Urology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
[2] Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong First Medical University &Shandong Academy of Medical Sciences, Jinan, Shandong, China.
[3] Department of Urology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China
[4] Central Laboratory, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
[5] Department of Pediatric Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China

Corresponding Author:
Qingyong Liu[1]
Jingshi Road, No. 16766, Jinan, Shandong, 250014, China
Email address: lqylbc@163.com
Zuohui Zhao[2]
Email address: zhaozuohui@126.com, zhaozuohui@sdhospital.com.cn

Abstract

Lactate dehydrogenase (LDH), a crucial glycolytic enzyme, mediates the metabolic plasticity of cancer cells, However whereas its clinical significance in renal cell carcinoma (RCC) is poorly understood. Herein, we examined the prognostic significance of the two primary components of LDH, i.e., LDHA and LDHB, in clear cell RCC (ccRCC) patients and further explored their association with immune infiltration in ccRCC. In this study, the expression levels of LDHA and LDHB were examined in ccRCC and adjacent normal tissues by Gene Expression Profiling Interactive Analysis 2 (GEPIA2), UALCAN, and western blotting (WB) analyses, and their prognostic values were estimated in 150 ccRCC and 30 adjacent normal tissues by immunohistochemistry (IHC) analysis. The relationship to immune infiltration of *LDHA* and *LDHB* genes was further investigated using tumor immune estimation resource 2 (TIMER2) and Tumor-Immune System Interactions and DrugBank (TISIDB) databases, respectively. Public databases and WB analyses demonstrated higher LDHA and lower LDHB in ccRCC than in non-tumor tissues. IHC analysis revealed that LDHA and LDHB expression profiles were significantly associated with tumor grade, stage, size, and overall survival (OS). Univariate survival analysis displayed that high grade, advanced stage, large tumor, metastasis, high LDHA, and low LDHB expression were significantly associated with a poorer OS, and multivariate analysis revealed tumor stage and LDHB were identified as independent predictors for OS in patients with ccRCC. Further TIMER and TISIDB analyses demonstrated that *LDHA* and *LDHB* expression was significantly related to multiple immune cells and immune inhibitors in over 500 ccRCC patients. These findings revealed that LDHB was an independent favorable predictor, and LDHA and LDHB correlated with tumor immune infiltrates in ccRCC patients, which indicated LDHA/LDHB could be implicated in the tumorigenesis of ccRCC and might be potential therapeutic targets for patients with ccRCC.

Introduction

Renal cell carcinoma (RCC) is the most common type of kidney cancer, with an estimated 79,000 newly diagnosed cases and 13,920 cancer-related deaths in the USA in 2022 (Siegel et al. 2022). Clear cell RCC (ccRCC) accounts for approximately 75 % of RCC and is refractory to traditional chemotherapy and radiotherapy (Posadas et al. 2017). Radical nephrectomy is the gold standard for localized RCC, which exhibits a good prognosis (about 80% five-year survival rate). However, the prognosis for patients with advanced RCC, especially metastatic RCC (mRCC), remains dismaying, due to their prone to relapse and resistance to conventional therapeutic approaches (Posadas et al. 2017). Although molecular targeted therapy could prolong the survival of advanced RCC patients, further exploration of the molecular mechanisms underlying RCC progression is urgently needed.

Metabolic reprogramming, or altered metabolism, is a critical hallmark of cancers, which facilitates accumulating metabolic intermediates as sources of building blocks (Jafari et al. 2019). In addition to aberrant metabolic pathways which cause lipid droplet (LDs) accumulation in ccRCC, recent evidence indicates a link between obesity and ccRCC, and ccRCC has been recognized as a chronic metabolic disease (Wettersten et al. 2017). Due to the paradox between uncontrolled cell proliferation and a limited supply of nutrients, cancer cells always reprogram their metabolism, including glucose, protein, nucleic acids, and lipids (Heravi et al. 2022). The first recognized and well-known metabolic reprogramming is aerobic glycolysis, which provides bulk intermediated products (including lactate and ATP) for the rapidly proliferating cancer cells even under normoxia (Wettersten et al. 2017). Delineating the mechanisms underlying metabolic reprogramming would facilitate understanding RCC's pathophysiology and provide a promising therapy for this heterogeneous tumor.

Lactate dehydrogenase (LDH), a nicotinamide adenine dinucleotide (NAD+) -dependent enzyme, is the crucial glycolytic enzyme involved in tumor initiation and metabolism. LDH is a tetrameric enzyme that catalyzes the reversible conversion of pyruvate to lactate, coupled with the oxidation of NADH to NAD+, in the glycolytic pathway (Urbanska & Orzechowski 2019). There are four subtypes of LDH, i.e., LDHA, LDHB, LDHC, and LDHD. Among them, LDHA and LDHB are the significant components of LDH, which mediate the metabolic plasticity of tumor cells. LDHA is abundant in skeletal muscle, which converts pyruvate to lactate and produces NAD+. In contrast, LDHB is predominantly expressed in the brain and heart, which



converts lactate to pyruvate for further oxidization (Ding et al. 2017; Urbanska & Orzechowski 2019). LDHC is mainly limited to the testis, while LDHD is universally found in various tissues (Urbanska & Orzechowski 2019).

Please include which study was the analysis done in?

Our previous proteomic analysis identified numerous dysregulated proteins, such as hydroxy acyl-CoA dehydrogenase alpha subunit (HADHA), LDHA, and LDHB, which might be implicated in RCC pathogenesis (Zhao et al. 2015). Recent literature reported that the isoenzymes of LDH, including LDHA, LDHC, and LDHD, were significantly correlated with the clinical outcomes of RCC (Girgis et al. 2014; Hua et al. 2017; Wang et al. 2018; Zhao et al. 2017). At the same time, the role of LDHB in RCC remains elusive. In addition, increasing evidence demonstrated the tight connection between LDH and tumor immune (Ding et al. 2017), which still needs further exploration. In the current study, we compared the differential expression of LDHA and LDHB between ccRCC and their adjacent kidney tissues using Gene Expression Profiling Interactive Analysis 2 (GEPIA2), UALCAN and western blotting (WB) analyses, detected their expression in 150 ccRCC and 30 normal kidney samples using immunohistochemistry (IHC) analysis with tissue microarray (TMA), assessed their prognostic role in the 150 ccRCC patients, and explored the relationship between *LDHA/LDHB* gene expression and immune infiltration in ccRCC using Tumor Immune Estimation Resource 2 (TIMER2) and Tumor-Immune System Interactions and DrugBank (TISIDB) databases, which aimed to investigate the clinical significance of LDHA and LDHB in patients with ccRCC (Fig. 1).

tumor immune? This sentence feels incomplete

Please mention if this was in the same set of patients or a seprate validation cohort of 150 patients.

Materials & Methods

Tissue samples and data collection

The ethical committees of The First Affiliated Hospital of Shandong First Medical University approved the research (2017-S007), and the participants signed the informed consent. Totally 157 ccRCC patients who underwent nephrectomy were enrolled in this study. All the ccRCC samples were primary lesions verified using hematoxylin and eosin (HE) staining after surgery. Cohort #1 was used to compare LDHA and LDHB expression by WB analysis, which consisted of 7 cases of ccRCC and their adjacent kidney tissues between March 2017 and January 2019 [including five males and two females, aged from 43 to 73, International Society of Urological Pathology (ISUP) grading with 1 G1 + 4 G2 + 2 G3, American Joint Committee on Cancer

(AJCC) pathological staging with 4 TI + 3 TII]. Cohort #2 was used to examine the expression and prognosis of LDHA and LDHB by IHC assay. TMA was provided by Outdo (Shanghai, China), which included 150 primary ccRCC and 30 adjacent normal tissues. The samples were collected between February 2008 and March 2010. The clinicopathological parameters of the 150 ccRCC patients were recorded, including tumor grade, stage, sizes, metastasis status, follow-up period, and the patient's sex and age (Table 1). The median follow-up period was 32.0 months (4 to 90 months).

LDH expression analysis

GEPIA2 (http://gepia2.cancer-pku.cn/) database was used to analyze the gene expression of the four subtypes of LDH, i.e., *LDHA, LDHB, LDHC*, and *LDHD,* in 523 ccRCC and 100 standard kidney samples from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx), as previously described (Huo et al. 2021; Tang et al. 2019). For correlation analysis, GEPIA2 was also used to validated the relationship between LDHB and the four immunoinhibitors, i.e., VTCN1, TGFBR1, ADORA2A and CD160, in the 523 ccRCC tissues. UALCAN (http://ualcan.path.uab.edu/analysis-prot.html) was used to compare the protein expression level of LDHA, LDHB, LDHC, and LDHD in ccRCC (Chandrashekar et al. 2022). The clinical proteomic tumor analysis consortium (CPTAC) module was used, and the total proteins of the four subtypes of LDH were compared between 110 ccRCC and 84 normal tissues, respectively.

Immunoblotting analysis

Why did the authors use DAB and not ECL. ECL is much more sensitive than DAB which is alo very toxic.
How were the developed Western Blots imaged?

As previously described, seven pairs of ccRCC and their adjacent tissues were used for WB analysis (Li et al. 2021). After incubating with the corresponding primary antibodies: LDHA (1:1,000, rabbit, #3582; CST, USA), LDHB (1:5,000, rabbit, ab53292; Abcam, USA), anti-Tubulin (1:2,000, rabbit, 11224-1-AP; Proteintech, China), horseradish peroxidase (HRP) conjugated secondary antibodies (1:5,000, rabbit, SA00001-2; Proteintech, China) were used to visualize the desired proteins. The protein bands were developed by 3,3'-diaminobenzidine (DAB, P0202, Beyotime, China) and quantified by Image J software.

Can WB data be quantified using ImageJ?

IHC analysis

The IHC analysis was performed on the TMA (n=150) as previously described (Li et al. 2021; Wu et al. 2022a). The slides were stained with primary antibodies: LDHA (1:400, CST) and LDHB (1:200, Abcam), developed with DAB (ZLI-9017; Zhongshan, China). The

What was configuration of the microscope, year, model, etc.

immunohistochemical staining was analyzed and reviewed on a microscope (Olympus, Tokyo, Japan) by two pathologists unaware of the disease outcome. As LDHA and LDHB were primarily located in the cytoplasm, immunoexpression was scored by evaluating the cytoplasmic staining intensity (0~3) and frequency (0~4) as previously described (Yuan et al. 2020). According to their expression, they were classified into two groups: low group (cancer scores <5 for LDHA, <6 for LDHB) and high group (scores ≥5 for LDHA, ≥6 for LDHB).

The prognosis analysis

Kaplan–Meier (K-M) plotter (www.kmplot.com) was used to validate the prognosis (recurrence-free survival, RFS) of *LDHA* in 530 ccRCC patients (Nagy et al. 2021). After being loaded into the database, the log-rank *P*-value and hazard ratio (HR) with 95% confidence intervals (CI) were calculated accordingly.

Human Protein Atlas (HPA) database (http://www.proteinatlas.org) was utilized to analyze and confirm the prognosis (OS) of *LDHB* in 528 ccRCC patients as previously reported (Fan et al. 2020). In the HPA database, the best expression cut-off was set as the default, and the prognosis indexes, i.e., K-M plot and log-rank *P*-value, were calculated after ≤150 months follow-up.

Immune infiltration analysis

TIMER2 (http://timer.cistrome.org/) and TISIDB (http://cis.hku.hk/TISIDB) databases were performed to reveal the relationship of *LDHA/LDHB* with immune infiltration in ccRCC, as previously described (Li et al. 2020; Ru et al. 2019). TIMER2 evaluated the abundance of eight tumor-infiltrating immune cells (TIIC) subsets, i.e., B cells, cancer-associated fibroblast, CD4+ T cells, CD8+ T cells, dendritic cells, endothelial cells, macrophages, and neutrophils, in the ccRCC cohort (n = 533). The expression data were log2 transcripts per million (TPM) transformed, Spearman was selected for correlation analysis, and multiple algorithms, including TIMER, OBERSORT, XCELL, and EPIC, were applied for immune infiltration estimations. TISIDB elucidated the correlations between *LDHA/LDHB* expression and abundance of tumor-infiltrating lymphocytes (TILs) & immune inhibitors in ccRCC (n = 534).

Statistical analysis

SPSS 21.0 software (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Student's t-test was performed for WB analysis to evaluate LDHA and LDHB expression. For IHC analysis, the Pearson chi-square test was used to assess the associations between LDHA/LDHB expression and clinicopathological parameters, the K-M survival curve was utilized to calculate overall

death, and Cox proportional hazard regression analysis was used to analyze the risk factors for ccRCC patient. For TIMER and TISIDB analyses, Spearman's correlations analysis was performed to estimate the correlation between *LDHA/LDHB* and tumor immune infiltrates. P <0.05 was considered statistically significant.

In some cases, patients have paired data; did authors use paired tests to assess statistical differences

Results

LDHA and LDHB expression in ccRCC

Please specify that the GEPIA2 database uses TCGA datasets. Please also include appropriate citations and links to the publicly available dataset.

First, we detected LDH expression levels between ccRCC and adjacent or normal kidney tissues. GEPIA2 database was performed to compare the transcriptional profile of the four subtypes of LDH, i.e., *LDHA, LDHB, LDHC, and LDHD,* in 523 ccRCC and 100 normal kidney tissues. The result demonstrated that *LDHA* mRNA was higher in cancerous than normal tissues ($P < 0.05$), *LDHB* and *LDHD* mRNA was lower ($P < 0.05$, and $P < 0.05$, respectively), and *LDHC* was unchanged in cancerous compared with normal tissues ($P > 0.05$, Fig. 2a, Fig. S1a). In addition, we assessed their protein expression using the CPTAC dataset. Consistently, it demonstrated higher LDHA, lower LDHB and LDHD, and stable LDHC expression in 110 ccRCC than 84 normal kidney tissues ($P < 0.001$, $P < 0.001$, $P < 0.001$, $P > 0.05$, Fig. 2b, Fig. S1b). LDHC is the testis-specific isoform, LDHD is universally expressed in various tissues, and their prognostic values in ccRCC have been reported previously (Hua et al. 2017; Wang et al. 2018). Herein, we focused on the significant components of LDH, i.e., LDHA and LDHB, in ccRCC. WB analysis showed that LDHA was significantly up-regulated and LDHB was down-regulated in the seven pairs of ccRCC than their non-cancerous specimens ($P < 0.001$, $P < 0.001$, respectively, Fig. 2c), which was consistent with GEPIA2 and ULACAN analyses.

Enhanced LDHA and decreased LDHB are associated with tumor aggressiveness of ccRCC

Subsequently, we evaluated LDHA/LDHB expression and its correlation with clinicopathological features in ccRCC patients (Table 1). IHC analysis showed that solid cytoplasm staining for LDHA expression was seen in the malignant cells of the kidney. In contrast, relatively weak staining for LDHB expression was seen in the neoplastic cells, compared with the adjacent kidney epithelial cells (Fig. 3). Specifically, more important positive signaling with LDHA was monitored in 94 (62.67 %) cases of ccRCC tissues, and weaker staining was examined in 56 (37.33 %) cases, respectively. The expression level of LDHA was higher in large tumors (≥ 7.0 cm) than in small ones (<7cm); the difference was statistically

What cancer markers were used to confirm the tissues imaged were indeed cancerous? Similarly, what markers were used to confirm that adjacent kidney cells were non-cancerous

include statistical test next to P values. Authors can also include expression level averages with SD in the parentheses

significant ($P< 0.001$). Simultaneously, enhanced LDHA expression (≥5 scores) was positively associated with high grade (grade 3-4, <0.001), advanced stage (stage II-III, P=0.001), older age (≥60 years, $P = 0.023$) and low overall survival (OS) rate ($P < 0.001$), which was consistent with a previous study (Girgis et al. 2014). There was no significant association between LDHA expression and patients' sex or metastatic status ($P = 0.724$, $P = 0.064$, respectively). As for LDHB, its reduced expression (<6 scores) was significantly associated with tumor grade ($P <$ 0.001), stage ($P < 0.001$), size ($P = 0.001$), metastasis ($P < 0.001$), and survival rate ($P < 0.001$), instead of patients' sex or age (P=0.618, $P = 0.111$, respectively). The further bioinformatic analysis demonstrated that LDHA showed a trend of positively associated with RFS ($P = 0.100$, Fig. S2a, K-M plotter) and *LDHB* expression was inverse associated with OS ($P = 0.004$, Fig. S2b, HPA), which validated our prognostic analysis using IHC. Collectively, these data revealed that high LDHA / low LDHB expression was positively associated with malignant behaviors such as pathological stage and tumor size, and negatively associated with OS, which indicated that high LDHA / low LDHB could be an indicator of tumor aggressiveness for patients with ccRCC. Furthermore, this is the first time to evaluate LDHB prognosis in ccRCC.

Though the association with metastatic status is not statistically-significant, It may yet be biologically relevant and the authors should note this

LDHB, but not LDHA, is an independent predictor of OS in patients with ccRCC.

To investigate the impact of LDHA/ LDHB expression on tumor prognosis, survival analysis was utilized to evaluate the correlation of their expression with the survival of ccRCC patients (n=150). During the follow-up period, K-M survival analysis manifested that the OS rate with high LDHA expression was significantly lower than that with low expression (log-rank=16.154, $P< 0.001$), while low LDHB expression was markedly correlated with high OS rate (log-rank=53.048, $P< 0.001$, Fig. 3).

Then univariate Cox regression analysis manifested that high LDHA expression was associated with poor prognosis for OS in ccRCC patients (HR 18.653, 95% CI = 2.534-137.309, $P = 0.004$, Table 2). Simultaneously, it demonstrated that large tumors (HR 5.004, 95% CI = 2.380-10.520, $P< 0.001$), high histological grade (HR 4.911, 95% CI = 2.264-10.650, $P< 0.001$), advanced pathological stage (HR 8.346, 95% CI = 3.931-17.722, $P< 0.001$), metastasis (HR 9.046, CI = 3.803-21.515, $P< 0.001$) and low LDHB expression (HR 0.017, 95% CI = 0.002-0.128, $P<$ 0.001), were all correlated with a shorter OS rate. Moreover, no association existed between OS and patients' sex or age ($P = 0.078$, $P = 0.128$, respectively). Furthermore, multivariate Cox regression analysis identified that pathological stage (HR 3.918, 95% CI = 1.827-8.400, $P<$

0.001) and LDHB (HR 0.025, 95% CI = 0.003-0.186, P< 0.001) were recognized as independent prognostic indicators for OS in ccRCC patients. In contrast, sex, age, grade, tumor size, metastasis, and LDHA expression were not identified as independent predictors.

TIMER and TISIDB analyses reveal the close relationship between LDHA/LDHB and immune infiltrates in ccRCC

Would it be prudent to use a multiple testing correction here? Clearly, CD4+T cells correlate highly with LDHB, more than any other immune cell type

We further performed data mining based on the expression and prognosis analysis of LDHA and LDHB in ccRCC. We investigated the correlation between the two subtypes of LDH, especially LDHB, and immune features, such as immune cells and immunomodulators, in ccRCC using TIMER and TISIDB databases. TIMER analysis displayed that *LDHB* gene expression was significantly associated with infiltration of seven TIIC subsets, i.e., B cell (rho = 0.109, P = 0.019), cancer-associated fibroblast (rho = -0.116, P = 0.013), CD4+ T cell (rho = 0.411, P < 0.001), CD8+ T cell (rho = -0.249, P < 0.001), endothelial cell (rho = -0.234, P < 0.001), macrophage (rho = 0.247, P = 0.001), and neutrophil (rho = 0.167, P < 0.001), except dendritic cell (rho = 0.021, P = 0.651) in the 533 ccRCC samples (Fig. 4). There was also a tight connection between LDHA and infiltration of TIICs, including B cell (rho = 0.129, P = 0.006), cancer-associated fibroblast (rho = -0.150, P = 0.001), CD4+ T cell (rho = -0.201, P < 0.001), CD8+ T cell (rho = -0.243, P < 0.001), endothelial cell (rho = 0.136, P = 0.003), dendritic cell (rho = 0.162, P < 0.001), and neutrophil (rho = 0.164, P < 0.001), except macrophage (rho = 0.086, P = 0.066) in the same ccRCC samples (Fig. S3). Simultaneously, TISIDB analysis revealed that LDHB expression was associated with the abundance of numerous TILs in the 534 ccRCC cases (Fig. 5). To be specific, LDHB expression was positively correlated with the abundance of immature dendritic cells (iDC, rho=0.363, P<0.001) and activated dendritic cell (Act_DC, rho=0.192, P<0.001), and inversely associated with the abundance of effector memory CD8+ T cell (Tem_CD8, rho=-0.366, P<0.001) and natural killer T cell (NKT, rho=-0.228, P<0.001). Similarly, LDHA expression was positively related to the abundance of immature dendritic cells (iDC, rho=0.383, P<0.001) and central memory $CD8^+$ T cell (Tcm_CD8, rho=0.301, P<0.001), and negatively correlated with the abundance of eosinophil cell (rho=-0.273, P<0.001) and activated B cell (Act_B, rho=-0.124, P=0.004, Fig. S4).

How do authors reconcile the conflicting results of the correlation of CD8+ T cells and LDHA expression between TISIDB and TIMER analysis

Moreover, we investigated the relationship between LDHB expression and the abundance of 24 immune inhibitors in ccRCC (Fig. 6). Specifically, the greatest positively correlated immunoinhibitors included B7 homolog 4 (B7-H4, or VTCN1, rho=0.235, P<0.001),

transforming growth factor-β receptor type I (TGFBR1, rho=0.112, *P*=0.009), and the negatively associated immunoinhibitors were adenosine A2a receptor (A2AR, ADORA2A, rho=-0.387, *P*<0.001) and CD160 (rho=0.339, *P*<0.001) in ccRCC. As for LDHA, the four immunoinhibitors with the greatest correlations included interleukin-10 receptor B (IL10RB, rho=0.412, *P*<0.001), indoleamine 2,3-dioxygenase 1 (IDO1, rho=0.154, *P*<0.001), CD112 (PVRL2, rho=0.090, *P*=0.039) and CD160 (rho=0.083, *P*=0.055) in ccRCC (Fig. S5). Furthermore, GEPIA2 analysis validated the tight relationship between *LDHB* and the four immunoinhibitors in 523 ccRCC tissues (Fig. S6). The above results implied that both LDHA and LDHB might be involved in regulating the immune infiltrates in ccRCC patients, which was consistent with previous reports (Ding et al. 2017).

Discussion

Aerobic glycolysis, or the Warburg effect, is the well-known and continually validated metabolic reprogramming of cancer. LDH is a critical enzyme involved in glycolysis and carcinogenesis, while its clinical significance in RCC has yet to be fully elucidated. Our previous study found numerous differentially expressed metabolic enzymes, such as HADHA, LDHA, and LDHB, in ccRCC tissues, implying the dysregulated metabolic pathways in the pathogenesis of ccRCC (Zhao et al. 2015). In the present study, we recapitulated that the major components of LDH, i.e., LDHA and LDHB, were promising indicators for prognosis and immune infiltration in ccRCC (Fig. 1). Our study validated the aberrant expression of LDHA and LDHB in ccRCC tissues, i.e., LDHA was up-regulated, and LDHB was down-regulated in ccRCC, consistent with previous reports (Girgis et al. 2014). Then retrospective IHC analysis revealed that the expression levels of LDHA and LDHB were significantly associated with tumor grade, stage, size, and OS, which indicated that enhanced LDHA and decreased LDHB were positively correlated with ccRCC aggressiveness. Subsequently, survival analysis revealed that LDHB, instead of LDHA, was recognized as an independent prognostic indicator for OS in 150 ccRCC patients. Further TIMER and TISIDB databases analysis manifested the close relationship between LDHA/LDHB expression and immune infiltrates (including immune cells and immune inhibitors) in >500 ccRCC patients, which indicates the complex tumor microenvironment (TME) of ccRCC. To our knowledge, this is the first time to elucidate the clinical significance of LDHB in ccRCC patients, which revealed that LDHB could be a favorable prognostic factor and might regulate

multiple immune features in ccRCC. Further studies are needed to explore the detailed mechanism underlying LDHB in ccRCC carcinogenesis.

Metabolic reprogramming, or metabolic plasticity, is an essential hallmark of cancers. It enables rapidly proliferating cancer cells to meet their needs for augmented energetics and building components. Emerging evidence illuminates the perturbed metabolic pathways which could control tumor energetics and biosynthesis in cancer, especially in ccRCC (Wettersten et al. 2017). Such aberrant metabolic pathways in ccRCC could provide opportunities to discover novel diagnostic biomarkers and therapeutic targets, which might improve the overall prognosis of ccRCC patients (Wettersten et al. 2017). In non-neoplastic or normal cells, glucose is converted to pyruvate, which undertakes oxidative phosphorylation (OXPHOS) for energy production under normoxia. Cancer cells predominantly produce energy and lactate by aerobic glycolysis, regardless of oxygen availability. ccRCC, characterized by high glucose uptake and enhanced levels/activities of glycolytic enzymes, such as hexokinase and LDHA, has been aptly labeled as a metabolic disease (Wettersten et al. 2017).

LDH isoenzymes are NAD+-dependent metabolic enzymes that are reportedly linked to RCC pathogenesis (Girgis et al. 2014; Hua et al. 2017; Wang et al. 2018; Zhao et al. 2017). LDH is the critical enzyme involved in aerobic glycolysis, which mediates metabolic plasticity through the bidirectional conversion of pyruvate and lactate. LDHA converts pyruvate to lactate and NADH to NAD+ in anaerobic conditions, whereas LDHB possesses a higher affinity for lactate, preferentially converting lactate to pyruvate when oxygen is abundant. As LDHA and LDHB participate in tumor cell metabolism and adaptation to detrimental cellular conditions, these enzymes are reportedly involved in tumor pathogenesis and progression (Urbanska & Orzechowski 2019). Except for LDHA and LDHB, LDHC and LDHD are expressed in various cancers (Urbanska & Orzechowski 2019). Previous studies showed elevated serum LDH was an unfavorable prognostic factor in RCC, especially metastatic RCC (Zhang et al. 2020). LDHA is overexpressed in various neoplastic tissues, and enhanced LDHA expression is associated with worse prognosis of patients with brain, liver, lung, and kidney tumors (Urbanska & Orzechowski 2019). Through IHC analysis, Girgis reported that overexpressed LDHA was associated with poor prognosis (including disease-free survival and OS) in 385 ccRCC patients, which validated its OS in an independent 170 ccRCC patients from TCGA databases (Girgis et al. 2014). This was a large-scale specimen, but it only evaluated the prognosis of LDHA. Zhao observed that

Did authors explore other methods of testing tumor tissue for LDHA/LDHB which have higher sensitivity?

elevated LDHA predicted worse survival in 43 ccRCC patients using IHC staining. LDHA knockdown attenuated tumor metastasis by inhibiting epithelial-mesenchymal transition (EMT) (Zhao et al. 2017). Similarly, Wang demonstrated the oncogenic role of LDHA in RCC cells, which indicated that LDHA might be a potential therapeutic target in RCC (Wang et al. 2017). As for LDHB, Wang observed that LDHB expression was higher in pancreatic cancer tissues using IHC analysis, and its expression was negatively correlated with prognosis (OS) in 50 pancreatic cancer patients (Wang et al. 2022). Interestingly, Wu found that LDHB expression was lower in glioma, and LDHB was identified as a protective factor using Chinese Glioma Genome Altas (CGGA) and TCGA databases (Wu et al. 2022b). The expression and prognosis of LDHB in cancer are controversial, and the clinical value of LDHB in ccRCC is unclear. Cancer–testis antigens (CTAs) are expressed in the testis and various cancers, and they are considered promising targets for early diagnosis and immunotherapy for cancers. As a member of CTAs, LDHC level was significantly up-regulated in RCC tissues, and the patients with positive LDHC expression had a shorter progression-free survival (PFS) in 133 RCC. Further in vitro experiments displayed that LDHC could promote RCC progression through EMT, indicating the oncogenic role of LDHC in RCC (Hua et al. 2017). Wang found that *LDHD* genes expression was considered to be a favorable predictive of the prognosis (OS) of ccRCC patients from TCGA (n=509) and Fudan University Shanghai Cancer Centre (FUSCC, n=192) cohorts, which indicated *LDHD* might be involved in ccRCC pathogenesis (Wang et al. 2018). Herein we identified LDHB as a favorable prognostic marker that closely correlated with immune infiltrates in ccRCC, and this is the first time to elucidate the clinical significance of LDHB in ccRCC to the best of our knowledge. LDHB converts lactate to pyruvate and produces NADPH, thus providing sufficient energy for tumor cell proliferation while avoiding the accumulation of lactate, which indicates it could be the potential therapeutic target for ccRCC, especially metastatic ccRCC.

Recent literature elaborates that the intermediates of cancer metabolism could be essential in regulating the proliferation, differentiation, and function of immune cells, which gives birth to immunometabolism (Shyer et al. 2020). Cancer cells, immune cells, secreted factors, and extracellular matrix proteins collectively constitute the complex dynamics of TME. Cancer cells can suppress the anti-tumor immune response by competing for and depleting essential nutrients and reducing the metabolic fitness of TIICs. Like cancer cells, TIICs require nutrients derived

from the TME to support their proliferation and differentiation. They also undergo metabolic reprogramming. During aerobic glycolysis, hypoxia, low pH, high levels of reactive oxygen species (ROS), and lactate accumulation are prevalent in the TME, which have a deleterious effect on the immune function (Harmon et al. 2020). Thus, the higher lactate content and the accompanying acidified TME will suppress immune cell function and abrogate immunosurveillance of cancer, ultimately leading to immune escape and cancer progression (Xia et al. 2021). In particular, lactate accumulation could deplete Teff cells and affect Treg cell infiltration, thus promoting the formation of an inhibitory immune microenvironment (Wang et al. 2021). Interestingly, Singer found that the increased GLUT-1 expression was correlated with a decrease in the numbers of infiltrating CD3+ and CD8+ T cells in 80 cases of ccRCC, suggesting that GLUT-1 might suppress the immune system in ccRCC (Singer et al. 2011). In the current study, we found there was a close correlation between LDHA and LDHB expression levels and multiple TIIC subsets, i.e., B cells, cancer-associated fibroblast, CD4+ T cells, CD8+ T cells, endothelial cells, and neutrophils, and massive immunoinhibitors such as VTCN1 (Fig. 4, 6). We identified LDHB as a favorable prognostic marker, and LDHA/LDHB was correlated with immune infiltrates in ccRCC, which confirmed the tight connection between immune and metabolism. Furthermore, the underlying molecular mechanism of immunometabolism still needs further investigation.

Which limited sample size are the authors referring to? Please be specific.

There are some limitations of this study. The first one is the limited sample size. Most of them are localized lesions, which need more specimens and prolonged follow-up periods to validate our results. The second shortcoming is that only one primary outcome, i.e., OS, is analyzed in the enrollment; CSS and RFS are also needed to clarify the clinical role of LDHA/LDHB in ccRCC. Finally, it should be marked that the detailed mechanism between LDHA/LDHB and tumor immune needs further clarification.

Another limitation is the lack of independent validation at protein level either through IHC or IF or flow cytometry of LDHA/LDHB levels in tissue with immune cell subtypes. Authors should address this in Discussion.

Conclusions

In the current study, we detected LDHA and LDHB expression using public databases and WB analyses, explored their prognostic role in ccRCC using TMA, then revealed the tumor-immune interaction of LDHA/LDHB in ccRCC using TIMER and TISIDB databases. These findings revealed that LDHB was an independent predictor of favorable survival. Both LDHA and LDHB were associated with tumor immune infiltrates in ccRCC patients, which suggested

LDHA/LDHB could be implicated in the tumorigenesis of ccRCC and might be potential therapeutic targets for patients with ccRCC.

References

Chandrashekar DS, Karthikeyan SK, Korla PK, Patel H, Shovon AR, Athar M, Netto GJ, Qin ZS, Kumar S, Manne U, Creighton CJ, and Varambally S. 2022. UALCAN: An update to the integrated cancer data analysis platform. *Neoplasia* 25:18-27. 10.1016/j.neo.2022.01.001

Ding J, Karp JE, and Emadi A. 2017. Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: Interplay between hematologic and solid neoplastic clones and their microenvironments. *Cancer Biomark* 19:353-363. 10.3233/CBM-160336

Fan D, Liu Q, Wu F, Liu N, Qu H, Yuan Y, Li Y, Gao H, Ge J, Xu Y, Wang H, Liu Q, and Zhao Z. 2020. Prognostic significance of PI3K/AKT/ mTOR signaling pathway members in clear cell renal cell carcinoma. *PeerJ* 8:e9261. 10.7717/peerj.9261

Girgis H, Masui O, White NM, Scorilas A, Rotondo F, Seivwright A, Gabril M, Filter ER, Girgis AH, Bjarnason GA, Jewett MA, Evans A, Al-Haddad S, Siu KM, and Yousef GM. 2014. Lactate dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma. *Mol Cancer* 13:101. 10.1186/1476-4598-13-101

Harmon C, O'Farrelly C, and Robinson MW. 2020. The Immune Consequences of Lactate in the Tumor Microenvironment. *Adv Exp Med Biol* 1259:113-124. 10.1007/978-3-030-43093-1_7

Heravi G, Yazdanpanah O, Podgorski I, Matherly LH, and Liu W. 2022. Lipid metabolism reprogramming in renal cell carcinoma. *Cancer Metastasis Rev* 41:17-31. 10.1007/s10555-021-09996-w

Hua Y, Liang C, Zhu J, Miao C, Yu Y, Xu A, Zhang J, Li P, Li S, Bao M, Yang J, Qin C, and Wang Z. 2017. Expression of lactate dehydrogenase C correlates with poor prognosis in renal cell carcinoma. *Tumour Biol* 39:1010428317695968. 10.1177/1010428317695968

Huo G, Wang Y, Chen J, Song Y, Zhang C, Guo H, Zuo R, Zhu F, Cui J, Chen W, Chen W, and Chen P. 2021. A Pan-Cancer Analysis of the Oncogenic Role of Twinfilin Actin Binding Protein 1 in Human Tumors. *Front Oncol* 11:692136. 10.3389/fonc.2021.692136

Jafari N, Drury J, Morris AJ, Onono FO, Stevens PD, Gao T, Liu J, Wang C, Lee EY, Weiss HL, Evers BM, and Zaytseva YY. 2019. De Novo Fatty Acid Synthesis-Driven Sphingolipid Metabolism Promotes Metastatic Potential of Colorectal Cancer. *Mol Cancer Res* 17:140-152. 10.1158/1541-7786.MCR-18-0199

Li N, Chen J, Liu Q, Qu H, Yang X, Gao P, Wang Y, Gao H, Wang H, and Zhao Z. 2021. Prognostic significance and tumor-immune infiltration of mTOR in clear cell renal cell carcinoma. *PeerJ* 9:e11901. 10.7717/peerj.11901

Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, and Liu XS. 2020. TIMER2.0 for analysis of tumor-infiltrating immune cells. *Nucleic Acids Res* 48:W509-W514. 10.1093/nar/gkaa407

Nagy A, Munkacsy G, and Gyorffy B. 2021. Pancancer survival analysis of cancer hallmark genes. *Sci Rep* 11:6047. 10.1038/s41598-021-84787-5

Posadas EM, Limvorasak S, and Figlin RA. 2017. Targeted therapies for renal cell carcinoma. *Nat Rev Nephrol* 13:496-511. 10.1038/nrneph.2017.82

Ru B, Wong CN, Tong Y, Zhong JY, Zhong SSW, Wu WC, Chu KC, Wong CY, Lau CY, Chen I, Chan NW, and Zhang J. 2019. TISIDB: an integrated repository portal for tumor-immune system interactions. *Bioinformatics* 35:4200-4202. 10.1093/bioinformatics/btz210

Shyer JA, Flavell RA, and Bailis W. 2020. Metabolic signaling in T cells. *Cell Res* 30:649-659. 10.1038/s41422-020-0379-5

Siegel RL, Miller KD, Fuchs HE, and Jemal A. 2022. Cancer statistics, 2022. *CA Cancer J Clin* 72:7-33. 10.3322/caac.21708

Singer K, Kastenberger M, Gottfried E, Hammerschmied CG, Buttner M, Aigner M, Seliger B, Walter B, Schlosser H, Hartmann A, Andreesen R, Mackensen A, and Kreutz M. 2011. Warburg phenotype in renal cell carcinoma: high expression of glucose-transporter 1 (GLUT-1) correlates with low CD8(+) T-cell infiltration in the tumor. *Int J Cancer* 128:2085-2095. 10.1002/ijc.25543

Tang Z, Kang B, Li C, Chen T, and Zhang Z. 2019. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. *Nucleic Acids Res* 47:W556-W560. 10.1093/nar/gkz430

Urbanska K, and Orzechowski A. 2019. Unappreciated Role of LDHA and LDHB to Control Apoptosis and Autophagy in Tumor Cells. *Int J Mol Sci* 20. 10.3390/ijms20092085

Wang R, Li J, Zhang C, Guan X, Qin B, Jin R, Qin L, Xu S, Zhang X, Liu R, Ye Q, and Cheng L. 2022. Lactate Dehydrogenase B Is Required for Pancreatic Cancer Cell

458 Immortalization Through Activation of Telomerase Activity. *Front Oncol* 12:821620.
459 10.3389/fonc.2022.821620
460 Wang X, Xu L, Wu Q, Liu M, Tang F, Cai Y, Fan W, Huang H, and Gu X. 2017. Inhibition of
461 LDHA Deliver Potential Anticancer Performance in Renal Cell Carcinoma. *Urol Int*
462 99:237-244. 10.1159/000445125
463 Wang Y, Li G, Wan F, Dai B, and Ye D. 2018. Prognostic value of D-lactate dehydrogenase in
464 patients with clear cell renal cell carcinoma. *Oncol Lett* 16:866-874.
465 10.3892/ol.2018.8782
466 Wang Z, He L, Li W, Xu C, Zhang J, Wang D, Dou K, Zhuang R, Jin B, Zhang W, Hao Q,
467 Zhang K, Zhang W, Wang S, Gao Y, Gu J, Shang L, Tan Z, Su H, Zhang Y, Zhang C,
468 and Li M. 2021. GDF15 induces immunosuppression via CD48 on regulatory T cells in
469 hepatocellular carcinoma. *J Immunother Cancer* 9. 10.1136/jitc-2021-002787
470 Wettersten HI, Aboud OA, Lara PN, Jr., and Weiss RH. 2017. Metabolic reprogramming in clear
471 cell renal cell carcinoma. *Nat Rev Nephrol* 13:410-419. 10.1038/nrneph.2017.59
472 Wu F, Chen J, Yao K, Fan D, Wang M, Liu Y, Xin S, Sun Z, Li S, Sun Y, and Liu Q. 2022a. The
473 Infiltration of Neutrophil Granulocytes Due to Loss of PTEN Was Associated with Poor
474 Response to Immunotherapy in Renal Cell Carcinoma. *J Inflamm Res* 15:6553-6567.
475 10.2147/JIR.S388990
476 Wu Z, Wang J, Li Y, Liu J, Kang Z, and Yan W. 2022b. Characterization of a lactate
477 metabolism-related signature for evaluation of immune features and prediction prognosis
478 in glioma. *Front Neurol* 13:1064349. 10.3389/fneur.2022.1064349
479 Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N, Yi P, Tang L, Pan Q, Rao S, Liang J, Tang Y, Su
480 M, Luo X, Yang Y, Shi Y, Wang H, Zhou Y, and Liao Q. 2021. The cancer metabolic
481 reprogramming and immune response. *Mol Cancer* 20:28. 10.1186/s12943-021-01316-8
482 Yuan Y, Yang X, Li Y, Liu Q, Wu F, Qu H, Gao H, Ge J, Xu Y, Wang H, Wang Y, and Zhao Z.
483 2020. Expression and prognostic significance of fatty acid synthase in clear cell renal cell
484 carcinoma. *Pathol Res Pract* 216:153227. 10.1016/j.prp.2020.153227
485 Zhang N, Zhang H, Zhu D, JiRiGaLa, Yu D, Wang C, WuYunBiLiGe, Amin, ZhiHong, Yu H,
486 Chen X, and Wang M. 2020. Prognostic role of pretreatment lactate dehydrogenase in
487 patients with metastatic renal cell carcinoma: A systematic review and meta-analysis. *Int*
488 *J Surg* 79:66-73. 10.1016/j.ijsu.2020.05.019

Zhao J, Huang X, Xu Z, Dai J, He H, Zhu Y, and Wang H. 2017. LDHA promotes tumor metastasis by facilitating epithelial-mesenchymal transition in renal cell carcinoma. *Mol Med Rep* 16:8335-8344. 10.3892/mmr.2017.7637

Zhao Z, Wu F, Ding S, Sun L, Liu Z, Ding K, and Lu J. 2015. Label-free quantitative proteomic analysis reveals potential biomarkers and pathways in renal cell carcinoma. *Tumour Biol* 36:939-951. 10.1007/s13277-014-2694-2

Figure 1

The workflow of prognosis and tumor-immune infiltration of LDHA/LDHB in ccRCC.



Figure 2

The expression profiling of LDHA and LDHB in ccRCC tissues.

Please include the statistical tests performed in Figure 2A, 2B and 2C (which has adjacent normal tissue)

A. The mRNA expression levels of LDHA and LDHB in 523 ccRCC and 100 normal kidney tissues (GEPIA2). B. The protein expression levels of LDHA and LDHB in 100 ccRCC and 84 normal kidney tissues (UALCAN). C. LDHA and LDHB protein expression in seven pairs ccRCC and their adjacent kidney tissues (WB). T: ccRCC, N: normal kidney tissues. *: $P<0.05$, **: $P<0.01$.

Please include all points



In the supplemental dataset file 1, please mark the lane numbers, the marker being looked at and the molecular weights. Why was the gel membrane cut?

Please include all points in bar plot & box and whisker's plot similar to figure 2A

Figure 3

The expression and prognosis of both LDHA and LDHB in 150 ccRCC tissues.

A. Representative immunostaining photomicrographs of LDHA and LDHB expression in ccRCC tissues (IHC). Staining signals displayed cytoplasmic localization of LDHA and LDHB in adjacent normal kidney and ccRCC tissues. Original magnification 200×; bars, 50 μm. Kaplan–Meier survival curves demonstrated overall survival of 150 patients with ccRCC, according to LDHA (B) and LDHB (C) staining.



Please label tissue type in each of the three IHC panels

I observe a variation in the tissue types imaged. Particular, the low expression group from the LDHA, it appars only fat cells have been imaged.

Please also comment on the morphological changes ocurrin due to the tumor itself. But for IHC comparisons, please try to image similar renal tissue as much as possible

Figure 4

Correlation between LDHB expression and tumor-infiltrating immune cells in 533 ccRCC patients (TIMER2).

The infiltration levels of the eight TIIC subsets, i.e., B cell (EPIC), Cancer associated fibroblast (EPIC), CD4+ T cell (EPIC), CD8+ T cell (TIMER), Endothelial cell (XCELL), Macrophage (TIMER), Myeloid dendritic cell (XCELL) and Neutrophil (OBERSORT).



Figure 5

Correlation between LDHB expression and lymphocytes in 534 ccRCC patients (TISIDB).

A: The pan-cancer analysis of relationship between LDHB expression and abundance of the 28 tumor-infiltrating lymphocytes (TILs). The top four lymphocytes either positive (B: iDC cell, C: Act_DC cell) or negative (D: Tem_CD8 cell, E: NKT) correlation with LDHB expression in ccRCC patients. *$P < 0.05$, **$P < 0.01$.



Figure 6

Correlation between LDHB expression and immunoinhibitors in 534 ccRCC patients (TISIDB).

A: The pan-cancer analysis of relationship between LDHB expression and abundance of the 24 immunoinhibitors. The top four immunoinhibitors [VTCN1 (B), TGFBR1 (C), ADORA2A (D) and CD160 (E)] either positively or negatively correlated with LDHB expression in ccRCC patients. *P< 0.05, **P< 0.01.



Table 1(on next page)

Correlation between LDHA and LDHB expression and clinical characteristics of ccRCC (n=150).

Table 1: Correlation between LDHA and LDHB expression and clinical characteristics of ccRCC (n=150)

Parameters	LDHA staining		χ^2	*P value*	LDHB staining		χ^2	*P value*
	Low (%)	High (%)			Low (%)	High (%)		
Sex								
Male (n=107)	39(36.45)	68(63.55)			42(39.25)	65(60.75)		
Female (n=43)	17(39.53)	26(60.47)	0.125	0.724	15(34.88)	28(65.12)	0.246	0.618
Age								
<60yrs (n=73)	34(46.58)	39(53.42)			23(31.51)	50(68.49)		
≥60yrs (n=77)	22(28.57)	55(71.43)	5.192	0.023	34(44.16)	43(55.84)	2.545	0.111
ISUP grade								
G 1-2 (n=103)	52(50.49)	51(49.51)			26(25.24)	77(74.76)		
G 3-4 (n=47)	4(5.41)	43(91.49)	24.305	<0.001	31(65.96)	16(34.04)	22.708	<0.001
AJCC stage								
T I (n=122)	54(44.26)	68(55.74)			36(29.51)	86(70.49)		
T II-III (n=16)	1(6.25)	15(93.75)			10(62.50)	6(37.50)		
T III (n=12)	1(8.33)	11(91.67)	13.412	0.001	11(91.67)	1(8.33)	22.480	<0.001
Tumor size								
<7.0 cm (n=119)	55(46.22)	64(53.78)			37(31.09)	82(68.91)		
≥ 7.0 cm (n=31)	1(3.23)	30(96.77)	19.430	<0.001	20(64.52)	11(35.48)	11.661	0.001
Metastasis								
Negative (n=140)	55(39.29)	85(60.71)			48(34.29)	92(65.71)		
Positive (n=10)	1(10.00)	9(90.00)	3.421	0.064	9(90.00)	1(10.00)	12.297	<0.001
Survival rate								
Alive (n=122)	55(45.08)	67(54.92)			30(24.59)	92(75.41)		
Dead (n=28)	1 (3.57)	27(96.43)	16.773	<0.001	27(96.43)	1(3.57)	49.884	<0.001

Statistical analyses were performed using Pearson chi-square tests.

Please include what the staining values mean, and how they were obtained in the table footer.

Do the LDHA and LDHB staining values correlate with ccRCC stage. If so, can authors include a figure showing that.

Table 2(on next page)

Univariate and multivariate survival analysis of overall survival (n=150).

Table 2: Univariate and multivariate survival analysis of overall survival (n=150).

Parameters	Univariate [a] HR (95% CI) [b]	*P*-value	Multivariate [a] HR (95% CI) [b]	*P*-value
Sex	0.386 (0.134-1.111)	0.078		
Age	1.823 (0.841-3.949)	0.128		
Grade (G3-4) [c]	4.911 (2.264-10.650)	<0.001		
Stage (TII-III) [d]	8.346 (3.931-17.722)	<0.001	3.918 (1.827-8.400)	<0.001
Size (≥7.0 cm)	5.004 (2.380-10.520)	<0.001		
Metastasis	9.046 (3.803-21.515)	<0.001		
High LDHA	18.653 (2.534-137.309)	0.004		
High LDHB	0.017 (0.002-0.128)	<0.001	0.025 (0.003-0.186)	<0.001

Note: [a] Statistical analysis by Cox proportional hazards regression model.

[b] Abbreviation: HR: hazard ratio, CI: confidence interval.

[c] For grade: 1, 2 vs 3-4.

[d] For stage: I vs II-III.